|
Age, mean ± SD, years
|
66.04 ± 9.69
|
64.10 ± 10.07
|
0.482
|
|
Male, n (%)
|
13 (56.53%)
|
21 (70.00%)
|
0.311
|
|
Overall survival, median, months
|
6.0 (4.0, 9.0)
|
9.0 (8.0, 15.5)
|
0.006b
|
|
Differentiation status
| |
0.523
|
|
Well differentiated
|
11 (20.75%)
|
17 (32.08%)
| |
|
Moderately to poorly differentiated
|
12 (22.64%)
|
13 (24.53%)
|
|
Tumor size, mean ± SD, cm
|
4.57 ± 1.40
|
3.75 ± 1.28
|
0.032b
|
|
Recurrences, n (%)
|
17 (73.91%)
|
20 (66.67%)
|
0.569
|
|
Location
| |
0.267
|
|
Head, n (%)
|
15 (28.30%)
|
18 (33.96%)
| |
|
Body/tail, n (%)
|
7 (13.21%)
|
20 (37.74%)
|
|
Diffusion involvement, n (%)
|
1 (1.89%)
|
2 (3.77%)
|
|
TNM stagea
| |
0.077
|
|
I–II stage, n (%)
|
14
|
24
| |
|
III–IV stage, n (%)
|
9
|
5
|
|
Lymph node metastasis, n (%)
|
14 (63.64%)
|
10 (35.71%)
|
0.0498*
|
|
Vascular Infiltration, n (%)
|
10 (43.48%)
|
3 (10.00%)
|
0.272
|
